Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-06-17T04:31:13.850Z Has data issue: false hasContentIssue false

Microtubule depolymerization in Uromyces appendiculatus by three new antineoplastic drugs: combretastatin A-4, dolastatin 10 and halichondrin B

Published online by Cambridge University Press:  01 March 1998

ROBERT W. ROBERSON
Affiliation:
Department of Botany, Box 871601, Arizona State University, Tempe, Arizona 85287-1601, U.S.A.
BRUCE TUCKER
Affiliation:
Cancer Research Institute, Box 872404, Arizona State University, Tempe, Arizona 85287-2494, U.S.A.
GEORGE R. PETTIT
Affiliation:
Cancer Research Institute, Box 872404, Arizona State University, Tempe, Arizona 85287-2494, U.S.A.
Get access

Abstract

Three new antineoplastic natural products, combretastatin A-4, dolastatin 10 and halichondrin B, have been evaluated for their antimicrotubule activity in Uromyces appendiculatus urediniospore germlings using indirect immunofluorescence microscopy. In control germlings microtubules were abundant and mostly oriented parallel to the longitudinal axis of the cell. The microtubule cytoskeleton of germlings treated with 1·3×10−5M (10 μg ml−1) dolastatin 10 and 4·5×10−5M (50 μg ml−1) halichondrin B disrupted the microtubule cytoskeleton resulting in the near elimination of microtubule-associated fluorescence. Combretastatin A-4 was less effective, requiring a concentration of 3·2×10−3M (1·0 mg ml−1) to disrupt the microtubule cytoskeleton. These effective doses are consistent with previously examined antimicrotubule agents (e.g. nocodazole, griseofulvin, vincristine sulphate, demecolcine).

Type
Research Article
Copyright
The British Mycological Society 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)